Sentence examples for mutations were treated from inspiring English sources

(A) A panel of melanoma cell lines that were homozygous null; heterozygous or homozygous positive for BRAFV600 mutations were treated with drug for 3 days, and FDG uptake was assessed (Asterisk, lines with increased FDG uptake from vemurafenib treatment).

Aged (11 12 month-old), double transgenic mice (n = 2) expressing APPswe and PSEN1dE9 mutations were treated with MRI-guided FUS-MB (Figure 1), and then received Trypan blue.

Stage IV patients with epidermal growth factor receptor (EGFR) mutations were treated with tyrosine kinase inhibitors.

In interim analysis of a single-arm, phase II study, 17 pretreated NSCLC patients carrying V600E BARF mutations were treated with dabrafenib [ 63].

Nine of ten patients with BRAF mutations were treated with BRAF inhibitors, either as a single agent (7 patients) or in combination with a MEK inhibitor (2 patients).

Colon cancer cells with and without oncogenic mutations such as KRAS and BRAF mutations were treated with erlotinib, an inhibitor of epidermal growth factor receptor, in order to detect the impact of these mutations on Raman spectra of the cells.

Although useful, frequency-based methods are limited in that all mutations are treated equally.

No patients with the mutation were treated with the latter two types of medication.

When the cells of the patient affected with the N273K mutation were treated for 5 days with increasing concentrations of glucosamine (Figure 5B) we found that the effect was proportional to the concentration of the inhibitor.

To understand whether similar effects could be also observed for other missense mutants the available primary cultures of skin fibroblasts from 9 MPS IIIC patients carrying missense HGSNAT mutations or a missense mutation in combination with a splice site or nonsense mutation were treated with glucosamine and assayed for N-acetyltransferase activity.

When HeLa cells stably expressing the R840C PAIS mutation were treated with the panel of agonists (Fig. 4, Table 1), they also demonstrated the ability to achieve increases in nuclear translocation similar to the wild type receptor (DHT: ↑ 21%; R1881: ↑ 29%; and, Mb: ↑ 29%), and at similar EC50 concentrations (DHT: 6.7 nM; R1881: 2.2 nM; and, Mb: 0.37 nM).